Hypogonadotropic Hypogonadism
Endocrinology
3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Mereo BioPharmaBGS649
Mereo BioPharmaBGS649
TakedaTAK-448
Clinical Trials (3)
Total enrollment: 15 patients across 3 trials
A 6 Month Safety Extension Study of MBGS205
Start: Nov 2016Est. completion: Nov 2018
Phase 2Completed
Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism
Start: May 2016Est. completion: May 2018
Phase 2Completed
A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism
Start: Feb 2015Est. completion: Nov 201515 patients
Phase 2Terminated
Related Jobs in Endocrinology
Research Associate I/II - Biology
Marea Therapeutics
South San Francisco
1w ago
$90K - $120K/yr
Associate Director, Clinical Operations
Marea Therapeutics
South San Francisco
3w ago
$190K - $210K/yr
Associate Director/Director, Regulatory Affairs
Marea Therapeutics
South San Francisco
1mo ago
$185K - $240K/yr
Medical Science Liaison (rare diseases)
Amgen
Poland - Lódz
1mo ago
Senior/Executive Director, Analytical Development
Marea Therapeutics
South San Francisco
1mo ago
$250K - $295K/yr
Senior Clinical Scientist - Job ID: 1845
Ascendis Pharma
Palo Alto, California (Hybrid)
2mo ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space